$8 Billion Opportunity: Inhibrx’s Experimental Cancer Drug Draws Major Interest

Inhibrx is drawing strong interest from Merck and other big pharma for its experimental cancer drug INBRX-106 that could boost Keytruda. Potential $9B spin-off value.